Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors

The CYP3A5*1 genetic polymorphism is a promising marker to identify heart transplant recipients least likely to develop renal dysfunction during long-term treatment with a calcineurin inhibitor.